Adverse pregnancy outcomes increase cardiovascular risk, even in unaffected sisters

Despite retaining ownership of CD388, Janssen is not planning to add the drug to its portfolio, but rather transfer CD388’s rights and obligations to a

Roche’s com­pe­ti­tion in the eye dis­ease space is in­ten­si­fy­ing with Re­gen­eron’s high-dose Eylea and a loom­ing biosim­i­lar chal­lenge, but the Swiss phar­ma said its block­buster